Consistent with our data in melanoma and PDAC, others have demonstrated that GPER signaling is tumor-suppressive in cancers that are not traditionally considered hormone responsive, including lung cancer, colon cancer, and melanoma (17–19). This evidence concerns the gene GPER1 and neoplasm.